Eli Lilly Buying Eye Disease Biotech For Up To $262M
Ropes & Gray LLP-advised Eli Lilly said Friday it has agreed to acquire Cooley LLP-guided Adverum Biotechnologies, a clinical-stage company developing gene therapies for eye diseases, for up to roughly $262...To view the full article, register now.
Already a subscriber? Click here to view full article